Spravato (Esketamine) for Treatment-Resistant Depression

Spravato (esketamine) is an FDA-approved nasal spray for adults with treatment-resistant depression (TRD) and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation. At CPS, Spravato is administered in-office under medical supervision through a REMS-certified program (Risk Evaluation and Mitigation Strategy — a required FDA safety program). This page is for patients who have tried multiple antidepressants without sufficient relief.

Unlike IV ketamine, Spravato is specifically FDA-approved for depression and is often covered by commercial insurance and Medicare. It works rapidly through the brain's glutamate system, targeting depression through a pathway that conventional SSRIs and SNRIs don't reach.

Our Spravato program integrates with CPS counseling, medication management, and when clinically appropriate our Intensive Outpatient Program (IOP — a structured treatment program involving several hours of therapy per week) for comprehensive care.